ACUMEN PHARMACEUTICALS INC (ABOS) Stock News

NASDAQ:ABOS - Nasdaq - US00509G2093 - Common Stock - Currency: USD

1.61 -0.07 (-4.17%)

After market: 1.6005 -0.01 (-0.59%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ABOS Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

10 days ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

15 days ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

2 months ago - By: Benzinga

A Preview Of Acumen Pharmaceuticals's Earnings

4 months ago - By: Benzinga

Preview: Acumen Pharmaceuticals's Earnings

15 days ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

2 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

2 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

3 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

4 months ago - By: Climb Bio, Inc. - Mentions: CLYM LENZ SLDB VERV

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

5 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

5 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

8 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

8 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

8 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

8 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

9 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

9 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference